𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

✍ Scribed by Laurence Klotz; Laurent Boccon-Gibod; Neal D. Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H. Schröder

Book ID
109055479
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
305 KB
Volume
102
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in alkaline phosphatase levels i
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
✍ Fritz H. Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D. S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

Study Type – Therapy (RCT)
Level of Evidence 1b ## OBJECTIVE To compare the activity of degarelix, a new gonadotrophin‐releasing hormone (GnRH) blocker, with leuprolide depot 7.5 mg in the control of total serum alkaline phosphatase (S‐ALP) levels in patients with prostate cancer. ## PATIENTS AND

Efficacy and safety of the PPARγ partial
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta

A phase 3 randomized controlled trial of
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro